SCHEMBL19434701

SCHEMBL19434701

Nc1nc(N/N=C/c2ccccc2O)cc(N/N=C/c2ccccc2O)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 9/20 0.59
▸ MEN1 O00255 6/20 0.59
▸ LMNA P02545 6/20 0.59
▸ MAPT P10636 8/20 0.55
▸ GAA P10253 7/20 0.55
▸ HPGD P15428 4/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ GFER P55789 2/20 0.55
▸ KDM4E B2RXH2 9/20 0.55
▸ HTT P42858 5/20 0.55
▸ L3MBTL1 Q9Y468 3/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ APAF1 O14727 1/20 0.55
▸ NSD2 O96028 1/20 0.55
▸ THRB P10828 1/20 0.55
▸ BLM P54132 1/20 0.55
▸ PPP1CA P62136 1/20 0.55
▸ SMN1; SMN2 Q16637 5/20 0.53
▸ TAAR1 Q96RJ0 3/20 0.53
▸ NPC1 O15118 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19434700 1.00 KMT2A (0.59) KMT2AMEN1LMNAMAPTGAA
SCHEMBL19449735 0.88 GAA (0.58) KMT2AMEN1LMNAMAPTGAA
SCHEMBL17560842 0.84 MEN1 (0.62) KMT2AMEN1LMNAMAPTGAA
SCHEMBL19449736 0.84 KMT2A (0.49) KMT2AMEN1LMNAMAPTGAA
SCHEMBL17560848 0.84 MEN1 (0.62) KMT2AMEN1LMNAMAPTGAA
SCHEMBL19434689 0.83 KDM4E (0.58) KMT2AMEN1LMNAMAPTGAA
SCHEMBL19434692 0.83 KDM4E (0.58) KMT2AMEN1LMNAMAPTGAA
SCHEMBL17560796 0.83 GAA (0.52) KMT2AMEN1LMNAMAPTGAA
SCHEMBL17560799 0.83 GAA (0.52) KMT2AMEN1LMNAMAPTGAA
SCHEMBL17560870 0.82 MAPT (0.57) KMT2AMEN1LMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3960729-A1 COMPOUNDS AND METHODS OF TREATING INFECTIONS Neoculi Pty Ltd (AU) 2022-03-02 — — EP claimed
US-10370341-B2 Compounds and methods of treating infections NEOCULI PTY LTD (AU) 2019-08-06 — — US claimed
US-10253002-B2 Compounds and methods of treating infections NEOCULI PTY LTD (AU) 2019-04-09 — — US claimed
US-20190084941-A1 COMPOUNDS AND METHODS OF TREATING INFECTIONS NEOCULI PTY LTD (AU) 2019-03-21 — — US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 — — US claimed
EP-2991968-B1 COMPOUNDS AND METHODS OF TREATING INFECTIONS NEOCULI PTY LTD (AU) 2021-11-10 — — EP disclosed
EP-3188722-B1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2021-08-04 — — EP disclosed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190084941-A1 COMPOUNDS AND METHODS OF TREATING INFECTIONS ELANE, IL1A, IL1B KMT2A 3325/4885MEN1 493/4885LMNA 3006/4885
US-10370341-B2 Compounds and methods of treating infections ELANE, IL1A, IL1B KMT2A 3325/4885MEN1 493/4885LMNA 3006/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS KMT2A 2912/4885MEN1 504/4885LMNA 2337/4885
US-10253002-B2 Compounds and methods of treating infections ELANE, IL1A, IL1B KMT2A 3325/4885MEN1 493/4885LMNA 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback